Evaxion A/S (EVAX)Healthcare | Biotechnology | Horsholm, Denmark | NasdaqCM
4.45 USD
+0.31
(7.488%)
⇧
(April 17, 2026, 4 p.m.
EDT)
After hours: 4.60 +0.15 (3.371%) ⇧ (April 17, 2026, 7:40 p.m. EDT) Short-term: ☆☆☆☆☆ | Long-term: ☆☆☆☆☆ | Dividends: ★☆☆☆☆ |
Hot Take | April 19, 2026, 12:19 a.m. EDT
Despite recent price strength and positive vaccine trial data extension news, EVAX presents a severe short-term bearish signal backed by 45-day model data predicting an 11% downside (-11% adjusted direction), absolute zero dividend yield due to zero recent payouts, and deteriorating fundamentals with negative revenue growth and deep unprofitability negating any long-term buy rating. |
| Model | MAE |
|---|---|
| AutoTheta ✓ | 0.225260 |
| MSTL | 0.272092 |
| AutoARIMA | 0.273896 |
| AutoETS | 0.273899 |
Forecast horizon: 45 days | Selected: AutoTheta
| Forecast Reliability | |
|---|---|
| Score | 80% |
| H-stat | 0.18 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.219 |
| Excess Kurtosis | -1.25 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 44.04 |
| Revenue per Share | 1.175 |
| Market Cap | 37,113,960 |
| Forward P/E | -7.38 |
| Beta | 0.20 |
| Profit Margins | -102.38% |
| Previous Name | Evaxion Biotech A/S |
| Website | https://evaxion.ai |
| Attribute | Value |
|---|---|
| 52 Week Change | 2.4099617 |
| Address1 | Dr. Neergaards Vej |
| Address2 | 5th Floor |
| All Time High | 1,252.0 |
| All Time Low | 1.2 |
| Ask | 5.27 |
| Ask Size | 2 |
| Average Daily Volume10 Day | 34,320 |
| Average Daily Volume3 Month | 43,911 |
| Average Volume | 43,911 |
| Average Volume10Days | 34,320 |
| Beta | 0.195 |
| Bid | 3.32 |
| Bid Size | 2 |
| Book Value | 2.043 |
| City | Horsholm |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Country | Denmark |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 4.45 |
| Current Ratio | 5.849 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,774,915,200 |
| Day High | 4.71 |
| Day Low | 4.04 |
| Debt To Equity | 44.04 |
| Earnings Call Timestamp End | 1,748,349,000 |
| Earnings Call Timestamp Start | 1,748,349,000 |
| Earnings Timestamp End | 1,755,520,200 |
| Earnings Timestamp Start | 1,755,001,800 |
| Ebitda | -8,873,000 |
| Ebitda Margins | -1.1786699 |
| Enterprise To Ebitda | -207.367 |
| Enterprise To Revenue | 244.417 |
| Enterprise Value | 1,839,967,872 |
| Eps Current Year | -0.64667 |
| Eps Forward | -0.60333 |
| Eps Trailing Twelve Months | -1.0 |
| Esg Populated | 0 |
| Exchange | NCM |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 3.6274 |
| Fifty Day Average Change | 0.8225999 |
| Fifty Day Average Change Percent | 0.22677398 |
| Fifty Two Week Change Percent | 240.99617 |
| Fifty Two Week High | 12.15 |
| Fifty Two Week High Change | -7.7 |
| Fifty Two Week High Change Percent | -0.63374484 |
| Fifty Two Week Low | 1.25 |
| Fifty Two Week Low Change | 3.1999998 |
| Fifty Two Week Low Change Percent | 2.56 |
| Fifty Two Week Range | 1.25 - 12.15 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,612,535,400,000 |
| Float Shares | 281,895,097 |
| Forward Eps | -0.60333 |
| Forward P E | -7.375731 |
| Free Cashflow | -4,449,750 |
| Full Exchange Name | NasdaqCM |
| Full Time Employees | 46 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Gross Margins | 1.0 |
| Gross Profits | 7,528,000 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.17469 |
| Held Percent Institutions | 0.07298 |
| Implied Shares Outstanding | 8,340,216 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Ipo Expected Date | 2,021-02-05 |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Last Split Date | 1,736,812,800 |
| Last Split Factor | 1:5 |
| Long Business Summary | Evaxion A/S, a clinical-stage biotech company, develops artificial intelligence-powered immunology vaccines. The company develops EVX-01, which is in phase 2 global multi-center clinical trial for the treatment of advanced melanoma; EVX-03, DNA-based cancer vaccine for the treatment of solid tumors; and EVX-04, a therapeutic cancer vaccine candidate, which is in phase 1 trial for acute myeloid leukemia. Its programs also include vaccines that are in pre-clinical stage, which includes EVX-B1, a multi-component prophylactic vaccine targeting skin and soft tissue infections with S. aureus bacteria; EVX-B2 to target multi-component prophylactic vaccine against gonorrhea bacteria; EVX-B3 to target bacterial pathogen associated with repeated infections; and EVX-V1, a multi-component prophylactic vaccine candidate for cytomegalovirus. The company was formerly known as Evaxion Biotech A/S and changed its name to Evaxion A/S in May 2025. Evaxion A/S was incorporated in 2008 and is based in Horsholm, Denmark. |
| Long Name | Evaxion A/S |
| Market | us_market |
| Market Cap | 37,113,960 |
| Market State | PREPRE |
| Max Age | 86,400 |
| Message Board Id | finmb_319014926 |
| Most Recent Quarter | 1,767,139,200 |
| Name Change Date | 2,026-04-19 |
| Net Income To Common | -7,707,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 37,047,235 |
| Number Of Analyst Opinions | 4 |
| Open | 4.18 |
| Operating Cashflow | -6,625,000 |
| Operating Margins | -1.2266201 |
| Payout Ratio | 0.0 |
| Phone | 45 53 53 18 50 |
| Post Market Change | 0.1500001 |
| Post Market Change Percent | 3.3707888 |
| Post Market Price | 4.6 |
| Post Market Time | 1,776,469,259 |
| Prev Name | Evaxion Biotech A/S |
| Previous Close | 4.14 |
| Price Eps Current Year | -6.8814077 |
| Price Hint | 4 |
| Price To Book | 2.1781693 |
| Price To Sales Trailing12 Months | 4.9301224 |
| Profit Margins | -1.02378 |
| Quick Ratio | 5.705 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | none |
| Region | US |
| Regular Market Change | 0.30999994 |
| Regular Market Change Percent | 7.487921 |
| Regular Market Day High | 4.71 |
| Regular Market Day Low | 4.04 |
| Regular Market Day Range | 4.04 - 4.71 |
| Regular Market Open | 4.18 |
| Regular Market Previous Close | 4.14 |
| Regular Market Price | 4.45 |
| Regular Market Time | 1,776,456,000 |
| Regular Market Volume | 113,264 |
| Return On Assets | -0.28226 |
| Return On Equity | -1.00175 |
| Revenue Growth | -1.0 |
| Revenue Per Share | 1.175 |
| Sand P52 Week Change | 0.38150132 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Shares Outstanding | 8,340,215 |
| Shares Percent Shares Out | 0.0045 |
| Shares Short | 37,653 |
| Shares Short Previous Month Date | 1,772,150,400 |
| Shares Short Prior Month | 52,498 |
| Short Name | Evaxion A/S |
| Short Percent Of Float | 0.0055 |
| Short Ratio | 1.11 |
| Source Interval | 15 |
| Symbol | EVAX |
| Target High Price | 16.0 |
| Target Low Price | 9.0 |
| Target Mean Price | 11.25 |
| Target Median Price | 10.0 |
| Total Cash | 23,234,000 |
| Total Cash Per Share | 0.056 |
| Total Debt | 7,504,000 |
| Total Revenue | 7,528,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -1.0 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 4.19669 |
| Two Hundred Day Average Change | 0.25330973 |
| Two Hundred Day Average Change Percent | 0.060359407 |
| Type Disp | Equity |
| Volume | 113,264 |
| Website | https://evaxion.ai |
| Zip | 2,970 |